These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 22631070)
41. Relationship between everolimus blood concentration assessed using the Innofluor Certican Fluorescence Polarization Immunoassay and the Architect i System sirolimus chemiluminescent microparticle immunoassay. Coentrão L; Carvalho C; Sampaio S; Oliveira JG; Pestana MI Transplant Proc; 2010 Jun; 42(5):1867-9. PubMed ID: 20620539 [TBL] [Abstract][Full Text] [Related]
42. Everolimus in cardiac-transplant recipients. Banas B; Böger C; Krämer B N Engl J Med; 2003 Dec; 349(23):2271-2; author reply 2271-2. PubMed ID: 14657441 [No Abstract] [Full Text] [Related]
43. Once daily everolimus is safe and effective in de novo renal transplant recipients: six-month results of a pilot study. Favi E; Spagnoletti G; Gargiulo A; Salerno MP; Romagnoli J; Citterio F Transplant Proc; 2010 May; 42(4):1308-11. PubMed ID: 20534287 [TBL] [Abstract][Full Text] [Related]
44. Everolimus: an immunosuppressive agent in transplantation. Patel JK; Kobashigawa JA Expert Opin Pharmacother; 2006 Jul; 7(10):1347-55. PubMed ID: 16805720 [TBL] [Abstract][Full Text] [Related]
45. Combination of everolimus and tacrolimus in kidney transplant patients with intolerance to mycophenolate mofetil/mycophenolic acid. Balda S; Inza A; Odriozola N; Zárraga S; García-Erauskin G; Lampreabe I Transplant Proc; 2009; 41(6):2095-8. PubMed ID: 19715841 [TBL] [Abstract][Full Text] [Related]
46. Everolimus in different combinations as maintenance immunosuppressive therapy in heart transplant recipients. Schweiger M; Stiegler P; Puntschart A; Sereinigg M; Prenner G; Wasler A; Tscheliessnigg K Exp Clin Transplant; 2012 Jun; 10(3):273-7. PubMed ID: 22631065 [TBL] [Abstract][Full Text] [Related]
47. Once-a-day administration of everolimus is safe in de novo renal transplant recipients: 1-year results of a pilot study. Spagnoletti G; Favi E; Gargiulo A; Salerno MP; Citterio F Transplant Proc; 2011 May; 43(4):1010-2. PubMed ID: 21620038 [TBL] [Abstract][Full Text] [Related]
48. Everolimus in liver transplantation. Trotter JF; Lizardo-Sanchez L Curr Opin Organ Transplant; 2014 Dec; 19(6):578-82. PubMed ID: 25254569 [TBL] [Abstract][Full Text] [Related]
49. Conversion to everolimus in kidney transplant recipients: to believe or not believe? Cotovio P; Neves M; Santos L; Macário F; Alves R; Mota A Transplant Proc; 2012 Dec; 44(10):2966-70. PubMed ID: 23195007 [TBL] [Abstract][Full Text] [Related]
50. Successful maternal and fetal outcome in a kidney transplant patient with everolimus exposure throughout pregnancy: a case report. Margoles HR; Gomez-Lobo V; Veis JH; Sherman MJ; Moore J Transplant Proc; 2014; 46(1):281-3. PubMed ID: 24507068 [TBL] [Abstract][Full Text] [Related]
52. Rationale for using belatacept in combination with sirolimus. Wéclawiak H; Kamar N; Ould-Mohamed A; Cardeau-Desangles I; Rostaing L Transplant Proc; 2010 Nov; 42(9 Suppl):S29-31. PubMed ID: 21095447 [TBL] [Abstract][Full Text] [Related]
53. Use of everolimus in renal transplant recipients: data from a national registry. Cicora F; Massari P; Acosta F; Petrone H; Cambariere R; González I; Imperiali N; López F; Otero A; Roberti J Transplant Proc; 2014 Nov; 46(9):2991-5. PubMed ID: 25420808 [TBL] [Abstract][Full Text] [Related]
54. Combination of everolimus with calcineurin inhibitor medication resulted in post-transplant haemolytic uraemic syndrome in lung transplant recipients--a case series. Lovric S; Kielstein JT; Kayser D; Bröcker V; Becker JU; Hiss M; Schiffer M; Sommerwerck U; Haller H; Strüber M; Welte T; Gottlieb J Nephrol Dial Transplant; 2011 Sep; 26(9):3032-8. PubMed ID: 21310739 [TBL] [Abstract][Full Text] [Related]
55. Bullous pemphigoid in a transplant recipient: is this a sign of allograft rejection? De Simone C; Caldarola G; Castriota M; Salerno MP; Citterio F Eur J Dermatol; 2012; 22(2):280-1. PubMed ID: 22381670 [No Abstract] [Full Text] [Related]
56. Renal recovery after conversion to an everolimus-based immunosuppression in early and late heart transplant recipients: a 12-month analysis. Michel S; Bigdeli AK; Hagl C; Meiser B; Kaczmarek I Exp Clin Transplant; 2013 Oct; 11(5):429-34. PubMed ID: 24128136 [TBL] [Abstract][Full Text] [Related]
57. Comparative analysis of adverse events requiring suspension of mTOR inhibitors: everolimus versus sirolimus. Sánchez-Fructuoso AI; Ruiz JC; Pérez-Flores I; Gómez Alamillo C; Calvo Romero N; Arias M Transplant Proc; 2010 Oct; 42(8):3050-2. PubMed ID: 20970607 [TBL] [Abstract][Full Text] [Related]
58. Generalized lymphedema in a sirolimus-treated renal transplant patient. De Bartolomeis C; Collini A; Rumberger B; Barni R; Ruggieri G; Bernini M; Carmellini M Clin Transplant; 2008; 22(2):254-7. PubMed ID: 18339149 [TBL] [Abstract][Full Text] [Related]